Michael Celano
Insider (Form 4 reporting owner): Director CIK 1377582Name as filed: Celano MichaelIts filings on EDGARAll insiders
Measures activity, not value. Not investment advice.
Since 31 Jan 2017, sold $1.1M in 4 sales and bought $223K in 4 open-market purchases across 2 companies.
Companies
Role on the latest Form 4 for each; open-market trades counted| Company | Role | Trades from | to | Purchases | Sales |
|---|---|---|---|---|---|
| OraSure Technologies OSUR | Director | 31 Jan 2017 | 12 Aug 2022 | 1$54K | 4$1.1M |
| Larimar Therapeutics LRMR | Chief Financial Officer | 16 Sep 2022 | 11 Nov 2026 | 3$169K | – |
What the share price did after their trades Share price return after each open-market trade, from the first close after the Form 4 became public, minus the return of the company's sector fund (the S&P 500 fund when the sector has none) over the same days. Median over the trades, in percentage points; at most one trade per company, side and month. It describes the past.
Median return minus the sector fund, in percentage points; "too few trades" under 5| Open-market trades | After 3 months | After 6 months | After 12 months |
|---|---|---|---|
| After purchases | too few trades3 trades | too few trades3 trades | too few trades3 trades |
| After sales | too few trades3 trades | too few trades3 trades | too few trades3 trades |
For a sale, a negative number means the shares did worse than the sector afterwards. It describes the past, not what comes next.
By year
Counted open-market trades, by trade date| Year | Purchases | Bought | Sales | Sold | Net |
|---|---|---|---|---|---|
| 2026 | 1 | $50K | – | – | $50K |
| 2023 | 1 | $19K | – | – | $19K |
| 2022 | 2 | $154K | – | – | $154K |
| 2017 | – | – | 4 | $1.1M | -$1.1M |
Every trade
8, newest first; open-market purchases and sales only| Trade date | Company | Side | Shares | Price | Value | Planned Rule 10b5-1 plan: the insider set the trade up in advance, so its timing says less about their view. The box exists on Form 4 since April 2023. | Filing |
|---|---|---|---|---|---|---|---|
| 11 Nov 2026 | Larimar Therapeutics LRMR | Buy | 18,460 | $2.71 | $50K | No | Form 4filed 12 Nov 2026 |
| 17 May 2023 | Larimar Therapeutics LRMR | Buy | 5,000 | $3.73 | $19K | No | Form 4filed 18 May 2023 |
| 16 Sep 2022 | Larimar Therapeutics LRMR | Buy | 31,746 | $3.15 | $100K | Not stated | Form 4filed 19 Sep 2022 |
| 12 Aug 2022 | OraSure Technologies OSUR | Buy | 12,000 | $4.49 | $54K | Not stated | Form 4filed 16 Aug 2022 |
| 5 May 2017 | OraSure Technologies OSUR | Sell | 44,962 | $14.95 | $672K | Not stated | Form 4filed 9 May 2017 |
| 2 Mar 2017 | OraSure Technologies OSUR | Sellafter exercising options | 15,000 | $12.00 | $180K | Not stated | Form 4filed 6 Mar 2017 |
| 9 Feb 2017 | OraSure Technologies OSUR | Sell | 10,000 | $10.06 | $101K | Not stated | Form 4filed 13 Feb 2017 |
| 31 Jan 2017 | OraSure Technologies OSUR | Sellafter exercising options | 15,000 | $8.78 | $132K | Not stated | Form 4filed 2 Feb 2017 |
From Form 4: open-market purchases (code P) and sales (code S) only; awards, option exercises, tax withholding and gifts are not counted. Greyed rows are amended copies or another filer's report of the same trade and count nowhere. Measures activity, not value. Not investment advice.